WULF vs. SRPT

In the year-to-date period, WULF achieves a -46.29% return, which is significantly higher than SRPT's -49.21% return. Over the past 10 years, WULF has underperformed SRPT with an annualized return of -13.27%, while SRPT has yielded a comparatively higher 16.73% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for TeraWulf Inc. (WULF) and Sarepta Therapeutics, Inc. (SRPT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current WULF Sharpe Ratio is 0.15, which is higher than the SRPT Sharpe Ratio of -0.77. The chart below compares the historical Sharpe Ratios of WULF and SRPT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither WULF nor SRPT has paid dividends to shareholders.

The maximum WULF drawdown since its inception was -98.50%, roughly equal to the maximum SRPT drawdown of -98.17%. Use the drawdown chart below to compare losses from any high point for WULF and SRPT. For additional features, visit the drawdowns tool.

TeraWulf Inc. (WULF) has a higher volatility of 40.18% compared to Sarepta Therapeutics, Inc. (SRPT) at 25.43%. This indicates that WULF's price experiences larger fluctuations and is considered to be riskier than SRPT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between TeraWulf Inc. and Sarepta Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.